Abiopharma

🔍 Rosenberg Nick (Executive)

Company: Metropolitan Bank Holding Corp. (MCB)

Report Date: 2026-06-26

Detailed Transactions and Holdings:

• Sold 263 shares of Common Stock at $100.0144 per share (Direct)
  Date: 2026-06-26 | Code: S | equity_swap_involved: 0 | shares_owned_after: 24,189.00 | transaction_form_type: 4 | Footnotes: F1, F2, F3
• Sold 90 shares of Common Stock at $100.055 per share (Direct)
  Date: 2026-06-29 | Code: S | equity_swap_involved: 0 | shares_owned_after: 24,099.00 | transaction_form_type: 4 | Footnotes: F1, F3
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-06-26 | Code: H | nature_of_ownership: By Child 1 | shares_owned_after: 250.00
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-06-26 | Code: H | nature_of_ownership: By Child 2 | shares_owned_after: 250.00
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-06-26 | Code: H | nature_of_ownership: By Child 3 | shares_owned_after: 20.00

Footnotes:

• F1: Sale effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person on June 6, 2025.
• F2: The $100.0144 price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.0000 to $100.1650, inclusive. The Reporting Person undertakes to provide to Metropolitan Bank Holding Corp., any security holder of Metropolitan Bank Holding Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote 2.
• F3: Includes restricted stock units granted on March 1, 2024 that vest at a rate of 33.3% per year commencing on March 1, 2025.
• F4: Includes restricted stock units granted on March 1, 2025 that vest at a rate of 33.3% per year commencing on March 1, 2026.
• F5: Includes restricted stock units granted on March 2, 2026 that vest at a rate of 33.3% per year commencing on March 2, 2027.